As the United States celebrates its 250th anniversary this year, Pfizer is reflecting on its own place in America’s long history of innovation and looking ahead to the next wave of discoveries we aim to achieve.

Founded in Brooklyn, New York, in 1849, Pfizer began with two entrepreneurs and a commitment to applying science to improve people’s lives. Nearly 180 years later, Pfizer colleagues continue to build on that legacy, advancing science with the potential to make a difference for people around the world.

From American Roots to Global Reach

Pfizer produces approximately 45 billion doses of more than 500 medicines and vaccines each year, reaching approximately 200 countries and territories. 

That scale is supported by colleagues working across research, development, manufacturing and supply to help turn scientific ideas into breakthroughs—and get them to the people who need them. 

Investing in What Comes Next

Pfizer has invested over $10 billion annually in internal research and development, and we operate 18 major R&D, manufacturing, and distribution facilities across the U.S. Today, our pipeline spans Oncology, Internal Medicine, Inflammation and Immunology, and Vaccines, with scientists working across a range of core modalities to pursue the next wave of innovation for patients around the world.

Pfizer is also working to become the most AI-forward company, using artificial intelligence across the business to help discover potential breakthroughs faster and accelerate their path to patients without compromising quality.

America’s 250th anniversary celebrates the people and ideas that have shaped the country. Pfizer is proud to be part of that broader story, and to continue building scientific progress as we pursue the discoveries still to come.